Headline
The latest stories from AHA Today.
The Senate Finance Committee today held a hearing on removing barriers to mental health care, with a focus on improving provider directory accuracy.
After reviewing a record 38,000 comments on proposed rules limiting telehealth prescriptions for buprenorphine and other controlled substances after the COVID-19 public health emergency, the Drug Enforcement Administration and Department of Health and Human Services “have decided to extend the…
ProMedica’s approach to integrating social determinants of health “is designed to offer a helping hand, not a prescribed intervention,” writes the health system’s director of community impact in Michigan.
Pregnant people with opioid use disorder are more likely to receive buprenorphine (a recommended treatment) if they are older, white and have public insurance.
AHA May 1 released a customizable video and other social media resources to help hospitals and health systems celebrate National Hospital Week.
The Centers for Medicare & Medicaid Services May 1 announced two investigations of hospitals that allegedly did not offer necessary stabilizing care to an individual experiencing an emergency medical condition in violation of the Emergency Medical Treatment and Labor Act.
AHA opposes the Centers for Medicare & Medicaid Services’ proposal to limit patient days when calculating Medicare Disproportionate Share Hospital payments for patients eligible for Medicaid benefits under a Section 1115 demonstration project, which it said could devastate access to care for…
The Government Accountability Office May 1 named six new members to the Medicaid and CHIP Payment and Access Commission, which advises Congress on issues affecting Medicaid and the Children’s Health Insurance Program.
The Food and Drug Administration April 28 authorized a fourth Pfizer COVID-19 bivalent vaccine dose at least one month after the third dose for certain immunocompromised children aged six months through 4.
The Food and Drug Administration last week alerted health care providers and laboratory personnel to a cybersecurity vulnerability affecting the Universal Copy Service software in certain Illumina medical devices used to sequence DNA for clinical diagnostic use or research.